Stock Ratings / Health Care / SXTP / options

EOCN (47) CVKD (40) GRI (38) ERNA (46) ⌘ Pro Terminal →

60 Degrees Pharmaceuticals Inc. (SXTP) Options Positioning, Max Pain & Unusual Sweeps

$0.95 +11.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

60 Degrees Pharmaceuticals Inc. (SXTP) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SXTP)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SXTP)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SXTP.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SXTP)

✓Walkthrough of SXTP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SXTP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -39.87%▼ DESCENDING CHANNEL

2026-10-30O $0.94H $0.97L $0.90C $0.95VOL 73.2K

RES: $1.59SUP: $0.57SMA50: $1.01SMA200: $1.77

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SXTP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SXTP Butterfly Map → + Track SXTP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +65.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SXTP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SXTP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SXTP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SXTP)

Health Care Rank #355 of 1016 ⚔️ EOCN vs SXTP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SXTP vs. EOCN, CVKD, GRI, ERNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, 60 Degrees Pharmaceuticals Inc. (SXTP) ranks #355 by composite RQD confidence (50/100, grade D) and #976 by equity capitalization ($3.3M). Within this direct 5-issuer industry benchmark cohort, SXTP leads on earnings valuation at N/A trailing P/E, while SXTP leads on capital efficiency and profitability with -35.0% ROIC and 22.3% gross margin. SXTP currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SXTP ACTIVE 60 Degrees Pharmaceuticals Inc.	D	50/100	—	22.3%	-35.0%	+11.87%	$3.3M	Benchmark Subject
EOCN Eocene Ltd.	D	47/100	—	—	-35.0%	+0.62%	$3.4M	/eocn-vs-sxtp →
CVKD Cadrenal Therapeutics Inc.	D-	40/100	—	—	-35.0%	-0.47%	$3.4M	/cvkd-vs-sxtp →
GRI GRI Bio Inc.	D-	38/100	—	—	-35.0%	-3.38%	$3.4M	/gri-vs-sxtp →
ERNA Ernexa Therapeutics Inc.	D	46/100	—	—	-35.0%	+6.57%	$3.4M	/erna-vs-sxtp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001946563

In its most recent audited fiscal period (FY2025, filed 2025-12-31), 60 Degrees Pharmaceuticals Inc. (SXTP) reported GAAP revenue of $1.0M (+65.5% vs. FY2024 revenue of $607.6K , and +296.5% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$6.8M, and free cash flow of -$7.0M (-21.5% YoY). On the balance sheet, SXTP closed FY2025 with $5.4M in total assets against $144.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.0M	-$7.4M	-$6.8M	-$7.0M	$5.4M	$144.0K
FY2024 (FY)	2024-12-31	$607.6K	-$7.9M	-$5.6M	-$5.8M	$5.8M	$147.1K
FY2023 (FY)	2023-12-31	$253.6K	-$3.8M	-$4.5M	-$4.5M	—	—

3. SXTP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SXTP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.95 (+11.87% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SXTP ranks #355 in composite RQD confidence.

How does SXTP compare to EOCN and CVKD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SXTP carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 22.3%, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and CVKD (Cadrenal Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M). Among the 5-stock peer group, SXTP leads on earnings multiple (N/A) while SXTP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SXTP?

Per SXTP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946563), 60 Degrees Pharmaceuticals Inc. generated $1.0M in revenue (+65.5% YoY), -$7.4M in net income, and -$7.0M in free cash flow against $5.4M in total assets and $144.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SXTP trading relative to its 50-day, 200-day, and 52-week technical levels?

SXTP last traded at $0.95 (+11.87% on volume of 358,283 shares), positioning the stock -5.94% below its 50-day simple moving average ($1.01) and -46.33% below its 200-day simple moving average ($1.77). Across its 52-week range of $0.59 to $8.62, SXTP sits at the 4.5% percentile with a 14-day RSI of 48.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.07).

SXTP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SXTP's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SXTP.

Direct Sub-Reports: SXTP RQD Cockpit SXTP 12M Forecast SXTP Earnings & Move SXTP Dividends & DRIP SXTP Insiders & 13F SXTP Whale Options SXTP Profit Sankey SXTP News & Why